Microbix Biosystems Inc. sees modest gains this week as it prepares for upcoming financial results.
Microbix Biosystems Inc. (MBX.TO) has seen a slight rise in its stock price this week, closing at C$0.29, which is a 1.64% increase. The company is getting ready to release its Q2 fiscal 2026 results on May 14, 2026. This announcement, along with other recent developments, has helped create a stable trading environment for the stock.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Microbix Biosystems Inc.
MBX.TO
MBX.TO
Microbix Biosystems Inc.
WealthAwesomeMarket cap
$42.63M
52W high
$0.34
52W low
$0.21
1W change
+1.64%
Beta
0.57
Analyst Price Targets
Based on analyst covering MBX
Wall Street analysts forecast MBX stock price to rise 29.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.40
+29.0% Upside
Current Price
C$0.31
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MBX's historical volatility
30-Day Vol
45.1%
Annualized
90-Day Vol
55.5%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$0.37
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$0.33 | C$0.28 โ C$0.38 |
| 60 trading days | C$0.35 | C$0.28 โ C$0.44 |
| 90 trading days | C$0.37 | C$0.28 โ C$0.49 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should keep an eye on the upcoming Q2 results and consider the companyโs recent performance metrics, such as revenue growth and market engagement, as potential indicators of future performance.
Microbix Biosystems Inc. Reports 29.17% YTD Gain
Despite ongoing losses, the company's stock has appreciated significantly since the start of the year, suggesting some optimism among investors.
Bull case
Positive revenue growth and upcoming product developments could indicate a turnaround for Microbix, making it an appealing option for long-term investors.
Bear case
The company continues to operate at a loss and faces challenges in achieving profitability, which may discourage risk-averse investors.
This Week's Price Action
Microbix Biosystems Inc. has shown modest performance this week, with its stock closing at C$0.29, reflecting a 1.64% increase over the past week. The stock has gained 29.17% year-to-date, indicating a positive trend despite some ongoing financial challenges.
Company News and Catalysts
While there was no major news this week, Microbix has been active in the diagnostics space, recently scheduling its Q2 fiscal 2026 earnings release for May 14, 2026. This anticipated event, along with a previous announcement of Q1 revenues showing a 13% increase, may spark investor interest.
Technical Picture
From a technical standpoint, Microbix's stock is currently trading above both its 50-day moving average of C$0.28 and its 200-day moving average of C$0.25, indicating positive momentum. The stock has a beta of 0.57, suggesting lower volatility compared to the overall market. The 52-week range of C$0.21 to C$0.34 indicates that the stock is trading at about 65% of its 52-week high, leaving room for potential growth.
Advertisement
